Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes


While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.


Renata Libianto, Timothy ME Davis, Elif I Ekinci

Learning Outcomes

  • Explain key components of the review.
  • List main recommendations.
  • Recognise changes in management as a result of the review.

Medical Journal of Australia
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Endocrine System Diseases
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Researcher, Retired, Specialist - Other, Specialist General Practitioner
You have to be logged in to see the content of this module.

Provided by